Insider Selling: Novartis AG (NYSE:NVS) Major Shareholder Sells 12,460 Shares of Stock

Novartis AG (NYSE:NVS) major shareholder Bioventures Ltd Novartis sold 12,460 shares of the business’s stock in a transaction dated Wednesday, July 25th. The stock was sold at an average price of $3.84, for a total transaction of $47,846.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures Ltd Novartis also recently made the following trade(s):

  • On Wednesday, August 1st, Bioventures Ltd Novartis sold 8,181 shares of Novartis stock. The stock was sold at an average price of $3.22, for a total transaction of $26,342.82.
  • On Monday, July 30th, Bioventures Ltd Novartis sold 2,000 shares of Novartis stock. The stock was sold at an average price of $3.27, for a total transaction of $6,540.00.
  • On Friday, July 27th, Bioventures Ltd Novartis sold 6,458 shares of Novartis stock. The stock was sold at an average price of $3.38, for a total transaction of $21,828.04.
  • On Monday, July 23rd, Bioventures Ltd Novartis sold 30,600 shares of Novartis stock. The stock was sold at an average price of $4.25, for a total transaction of $130,050.00.
  • On Monday, July 16th, Bioventures Ltd Novartis sold 300 shares of Novartis stock. The stock was sold at an average price of $5.15, for a total transaction of $1,545.00.

Shares of Novartis opened at $82.10 on Friday, MarketBeat.com reports. The company has a quick ratio of 0.89, a current ratio of 1.15 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $193.60 billion, a P/E ratio of 17.07, a price-to-earnings-growth ratio of 1.85 and a beta of 0.82. Novartis AG has a fifty-two week low of $72.30 and a fifty-two week high of $94.19.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, July 18th. The company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.02. The firm had revenue of $13.16 billion during the quarter, compared to analysts’ expectations of $12.93 billion. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.22 earnings per share. research analysts predict that Novartis AG will post 5.06 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Winthrop Partners WNY LLC acquired a new position in Novartis during the 1st quarter worth approximately $100,000. Gables Capital Management Inc. acquired a new position in Novartis during the 1st quarter worth approximately $103,000. Archford Capital Strategies LLC acquired a new position in Novartis during the 1st quarter worth approximately $149,000. Quad Cities Investment Group LLC acquired a new position in Novartis during the 2nd quarter worth approximately $139,000. Finally, Private Capital Group LLC boosted its holdings in shares of Novartis by 410.8% in the 1st quarter. Private Capital Group LLC now owns 2,467 shares of the company’s stock valued at $204,000 after buying an additional 1,984 shares in the last quarter. Institutional investors own 10.93% of the company’s stock.

A number of equities analysts have commented on NVS shares. Deutsche Bank reaffirmed a “neutral” rating on shares of Novartis in a research note on Friday, April 20th. ValuEngine downgraded shares of Novartis from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, May 17th. Credit Suisse Group raised shares of Novartis from an “underperform” rating to a “neutral” rating in a research note on Friday, May 25th. Finally, HSBC downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, May 29th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $93.50.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Further Reading: Google Finance Portfolio Workaround

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply